NCT02047461View on ClinicalTrials.gov

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2022

Study Completion Date

October 31, 2022

Conditions
Molybdenum Cofactor Deficiency, Type A
Interventions
DRUG

ORGN001 (formerly ALXN1101)

IV infusion

Trial Locations (6)

53226

Children's Hospital of Wisconsin, Milwaukee

Unknown

Monash Medical Centre, Melbourne

Beatrix Children's Hospital, Groningen

Unité des maladies métaboliques, Tunis

Royal Hospital for Sick Children, Glasgow

Manchester University Hospitals NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

Origin Biosciences
All Listed Sponsors
lead

Origin Biosciences

INDUSTRY